ALFA Finder| Revenue growth | FY26 sales reached Rs 582 Bn, showing strong historical 17% CAGR. |
|---|---|
| Margins | Gross margin reached 80.2%; EBITDA margin expanded to 30.3% in FY26. |
| Demand visibility | Strong; No. 1 prescriber share in 11 categories in India. |
| Management confidence | High; emphasizing 'Best-in-class profitability' and strong 20.7% ROCE. |
Growth
FY26 sales grew to Rs 582 Bn; 10-year CAGR (FY10-25) was 17% for sales and 16% for EBITDA.
Outlook
Focus on high-value Innovative Medicines (22% of FY26 sales) and R&D (6.1% of sales) for long-term sustainable growth.
Risks
Regulatory compliance, successfully implementing expansion plans, and market risks in over 100 operating countries.
Last quarter's promises, checked
Delivered
- Guided R&D spend 6% to 7% of sales → delivered 6.7% (= BEAT)
- Guided Innovative R&D to increase → delivered 36.9% of total R&D (= BEAT)
- Guided Innovative Medicines growth → delivered 16.8% for FY26 (= BEAT)
Partly delivered
- Guided U.S. sales growth → delivered marginal decline in FY26 (= PARTIAL)
Earnings Call filed with NSE, NSE: SUNPHARMA. Summary written with AI assistance from the document.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,902.30
- Market cap
- ₹4,56,426 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 41.6×Sector 43.8×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Price Movement Clarification
Sun Pharma said a 30 October 2026 news report concerned August 2026 developments, not new events. It confirmed no undisclosed material information explains the share price movement.
Sun Pharmaceutical Industries Annual General Meeting
Sun Pharma's postal ballot passed all seven special resolutions, including ESOP 2026 approval and borrowing and security limits. No monetary transaction is stated.
Sun Pharmaceutical Industries Earnings Call Transcript: Key Takeaways
Sun Pharma delivered resilient double-digit revenue growth despite U.S. specialty headwinds, masking underlying margin pressure from lower Lenalidomide sales.
Sun Pharmaceutical Industries Other Announcement
Sun Pharma's board appointed Deloitte as Statutory Auditors under mandatory rotation, effective from the FY 2026-27 AGM. This follows SRBC & CO's second five-year term completion.
Sun Pharmaceutical Industries Q2 FY27 Results: Net Profit ₹1,995 Cr, Down 36.2% YoY
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹16,199 Cr (+11.9% YoY) and net profit of ₹1,995 Cr (-36.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,995 Cr · -36.2% YoY
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.